Every 10-Q that DaVita Inc. (DVA) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow DVA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full DVA filings page.
DaVita Inc. reported higher results for the three months ended March 31, 2026, with total revenues of $3,415.5M versus $3,223.5M a year earlier. Net income attributable to DaVita rose to $197.5M from $162.9M, and diluted EPS increased to $2.87 from $2.00.
U.S. dialysis remained the core business, generating $2,941.7M of revenue and operating income of $506M, while ancillary services produced $498M of revenue and modest operating income of $6M. Consolidated operating income grew to $481.9M from $438.9M.
Operating cash flow strengthened to $320.8M from $180.0M, supporting capital spending of $102.0M and share repurchases of 3.0 million shares for $402.9M. Long-term debt totaled $10,626.3M in principal, and DaVita signed an agreement to buy a roughly $200M minority stake in Elara Caring, pending customary approvals.
DaVita Inc. filed its Q3 2025 10‑Q, reporting higher revenue and continued buybacks. Total revenues were $3,420,227 thousand, up from $3,263,590 thousand a year ago. Operating income was $505,767 thousand. Net income attributable to DaVita Inc. was $150,332 thousand, with diluted EPS of $2.04.
For the first nine months, revenues reached $10,023,282 thousand and net cash provided by operating activities was $1,345,774 thousand. The company repurchased 3,274 thousand shares in Q3 for $465,141 thousand and 10,001 thousand shares year‑to‑date for $1,461,387 thousand. As of October 28, 2025, approximately 70.6 million shares were outstanding.
DaVita issued $1,000,000 of 6.75% senior notes due 2033 and refinanced into a Term Loan B‑2 of $1,873,254; long‑term debt stood at $10,183,863 thousand. The weighted average effective interest rate on all debt was 5.70% in Q3. The company acquired Fresenius Medical Care’s Brazil dialysis operations for $94,282 thousand, contributing to total 2025 acquisition consideration of $108,015 thousand.